Proact

Proact

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Proact - Favourable market conditions in Q3e as well

16 juli 2026

  • A combination of growth and cost reductions...
  • .. and a balance between pricing tailwinds & extended lead times
  • Small revisions to estimates, adj. EBITA +0-2%

Combining top-line growth with lower costs

Q2 adj. EBITA was 7% better than we expected, growing 39% y-o-y on a combination of 10% revenue growth and 1% lower opex. The system sales market remains volatile, however, due to the sharp increase in memory prices. While serving as a tailwind to growth, it is also a headwind on volumes, as it extends delivery times in the market. We therefore expect the 12% organic growth in system sales to rise further to 15% in Q3e before coming down to 2% in Q4e, which we view as relatively in line with Proact's comments about a favourable set-up in Q3 and more uncertainty in Q4. The uncertainty in Q4 is mostly related to the longer delivery times and whether some deliveries will be pushed into 2027. The cost programme in 2025 is bearing fruit and the lower cost base should prove sustainable ahead.

Small estimate revisions

As the report was broadly in line with our estimates, we make only minor revisions. System sales are slightly higher while service sales are slightly lower, leaving our group sales forecast almost unchanged. On adj. EBITA, we raise 2026e by 2% while leaving 2027-28e unchanged, but we acknowledge relatively high estimate uncertainty ahead.

Share at 7.6x 2026e EV/adj. EBITA

On our updated estimates, the share is trading at 7.6x 2026e EV/adj. EBITA, and we currently expect -4% adj. EBITA growth in 2027e driven by a normalisation in the market and somewhat higher costs. Near-term, we expect earnings growth to be strong, with adj. EBITA +33% y-o-y in Q3e. Proact will hold a CMD in H2'26, and given the current LTM adj. EBITA margin of 7.9% vs. its target of >8% it will be interesting to see if it raises its margin target or intensifies growth plans.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys